Loading this company
Vertex Pharmaceuticals Incorporated
VRTXPrices in USD
TickerWorth ScoreC50/100
What we think
Priced above our range of $169.40 to $417.82.
Price
$499.74USD down −$9.01 (−1.77%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$169.40–$417.82
What the price needs: revenue growth of 15.5%/yr for 5 years (our model assumes 10.4%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $499.74Priced · Prices are delayed.
Is it a good business?
- Valuation17 out of 100
- Growth83 out of 100
- Financial health100 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$571.46 across 28 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 6,400 people.
Key stats
52-week range$403.16–$560.25
- Open
- $511.06
- Day high
- $512.21
- Day low
- $497.49
- Previous close
- $508.75
- Volume
- 1,413,287 · 1.20× avg
- Average volume
- 1,173,328
- Market cap
- $126,584,135,680.00
- P/E (TTM)
- 29.11
- Earnings per share
- $17.17
- Beta
- 0.28
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Changed leadership or its board
- Reported quarterly or annual results
- Signed a material agreement
- Changed leadership or its board
- Reported quarterly or annual results
- Changed leadership or its board
- Disclosed another material event
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- van Grunsven JasperGrant / award · —
- Ambrose KristenGrant / award · —
- SACHS BRUCE I
Not investment advice. TickerWorth Score is a model output.